Lorazepam
- Generic Name
- Lorazepam
- Brand Names
- Ativan, Loreev
- Drug Type
- Small Molecule
- Chemical Formula
- C15H10Cl2N2O2
- CAS Number
- 846-49-1
- Unique Ingredient Identifier
- O26FZP769L
- Background
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
- Indication
Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.
...
- Associated Conditions
- Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus
- Associated Therapies
- Anesthetic premedication therapy
Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-22
- Target Recruit Count
- 60
- Registration Number
- NCT06370442
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Laureate Institute for Brain Research, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT06004115
- Locations
- 🇺🇸
Laureate Institute for Brain Research, Tulsa, Oklahoma, United States
Therapies for Down Syndrome Regression Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 66
- Registration Number
- NCT05662228
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Zhenghui YI
- Target Recruit Count
- 300
- Registration Number
- NCT05599126
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity
- Conditions
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 20
- Registration Number
- NCT04923659
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
- Conditions
- Interventions
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- InterveXion Therapeutics, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT04715230
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Sacred Heart Medical Center, Spokane, Washington, United States
🇺🇸University of New Mexico Hospital, Albuquerque, New Mexico, United States
Multimodal Analgesia Effect on Post Surgical Patient
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 60
- Registration Number
- NCT04240626
- Locations
- 🇺🇸
UC Davis Health, Sacramento, California, United States
Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- OSF Healthcare System
- Target Recruit Count
- 142
- Registration Number
- NCT04156464
- Locations
- 🇺🇸
OSF Saint Francis Medical Center, Peoria, Illinois, United States
LORA-PITA IV General Investigation
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 206
- Registration Number
- NCT03905798
- Locations
- 🇯🇵
Pfizer Local Country office, Tokyo, Shibuya-ku, Japan
Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine
- Conditions
- Interventions
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Santa Barbara Cottage Hospital
- Registration Number
- NCT03788889
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.